Global Prescription Weight Loss Pills Market Growth 2023-2029

Global Prescription Weight Loss Pills Market Growth 2023-2029

The global Prescription Weight Loss Pills market size is projected to grow from US$ 1105.4 million in 2022 to US$ 2264.6 million in 2029; it is expected to grow at a CAGR of 10.8% from 2023 to 2029.

United States market for Prescription Weight Loss Pills is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Prescription Weight Loss Pills is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Prescription Weight Loss Pills is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Prescription Weight Loss Pills players cover Currax Pharmaceuticals (Contrave), VIVUS (Qsymia), Novo Nordisk A/S, Rhythm Pharmaceuticals (Imcivree), Eli Lilly and Company (TRICARE), CHEPLAPHARM (Xenical), Pfizer, Teva Pharmaceutical (Actavis) and Haleon Group (alli), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Health care professionals use the Body Mass Index (BMI), a measure of people weight in relation to height, to define overweight and obesity. People who have a BMI between 25 and 30 are considered to be overweight. Obesity is defined as having a BMI of 30 or greater. Are overweight, obese, or severely obese, which may increase risk of developing health problems. Obesity is a chronic disease and prescription medications to treat overweight and obesity work in different ways. Prescription weight loss medicines can help obese people lose weight. They are usually prescribed by a doctor when diet and exercise alone are not working. Each of these medicines works differently. People who use these medicines may not feel as hungry. Or they may feel full after eating only a small amount of food. Another type of weight-loss medicine makes it harder for your body to absorb fat. Prescription weight loss drugs can be helpful when used in combination with a low-calorie diet and regular physical activity.

LPI (LP Information)' newest research report, the “Prescription Weight Loss Pills Industry Forecast” looks at past sales and reviews total world Prescription Weight Loss Pills sales in 2022, providing a comprehensive analysis by region and market sector of projected Prescription Weight Loss Pills sales for 2023 through 2029. With Prescription Weight Loss Pills sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prescription Weight Loss Pills industry.

This Insight Report provides a comprehensive analysis of the global Prescription Weight Loss Pills landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prescription Weight Loss Pills portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Prescription Weight Loss Pills market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prescription Weight Loss Pills and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prescription Weight Loss Pills.

This report presents a comprehensive overview, market shares, and growth opportunities of Prescription Weight Loss Pills market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Oral Tablets
Oral Capsules
Injections

Segmentation by application
Hospital
Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)

Key Questions Addressed in this Report

What is the 10-year outlook for the global Prescription Weight Loss Pills market?

What factors are driving Prescription Weight Loss Pills market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Prescription Weight Loss Pills market opportunities vary by end market size?

How does Prescription Weight Loss Pills break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.